Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

被引：84

作者：

Lleo, Alberto ^{[1
,2
]}

Alcolea, Daniel ^{[1
,2
]}

Martinez-Lage, Pablo ^{[3
]}

Scheltens, Philip ^{[4
,5
]}

Parnetti, Lucilla ^{[6
]}

Poirier, Judes ^{[7
]}

Simonsen, Anja H. ^{[8
]}

Verbeek, Marcel M. ^{[9
,10
]}

Rosa-Neto, Pedro ^{[7
]}

Slot, Rosalinde E. R. ^{[4
,5
]}

Tainta, Mikel ^{[3
]}

Izaguirre, Andrea ^{[3
]}

Reijs, Babette L. R. ^{[11
]}

Farotti, Lucia ^{[6
]}

Tsolaki, Magda ^{[12
,13
]}

Vandenbergue, Rik ^{[14
,15
]}

Freund-Levi, Yvonne ^{[16
,17
]}

Verhey, Frans R. J. ^{[11
]}

Clarimon, Jordi ^{[1
,2
]}

Fortea, Juan ^{[1
,2
]}

Frolich, Lutz ^{[18
]}

Santana, Isabel ^{[19
,20
]}

Luis Molinuevo, Jose ^{[21
]}

Lehmann, Sylvain ^{[22
]}

Visser, Pieter J. ^{[4
,5
,11
]}

Teunissen, Charlotte E. ^{[4
,5
]}

Zetterberg, Henrik ^{[23
,24
,25
,26
]}

Blennow, Kaj ^{[23
,24
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain

[2] Ctr Biomed Invest Network Neurodegenerat Dis CIBE, Madrid, Spain

[3] Fdn CITA Alzheimer Fundazioa, Ctr Res & Adv Therapies, San Sebastian, Spain

[4] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam UMC, Neurosci Campus Amsterdam, Amsterdam, Netherlands

[5] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, Neurosci Campus Amsterdam, Amsterdam, Netherlands

[6] Univ Perugia, Sect Neurol, Lab Clin Neurochem, Ctr Memory Disturbances, Perugia, Italy

[7] Douglas Mental Hlth Univ Inst, Ctr Studies Prevent Alzheimers Dis, Montreal, PQ, Canada

[8] Univ Copenhagen, Danish Dementia Res Ctr, Rigshosp, Copenhagen, Denmark

[9] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol,Radboud Alzheimer Ctr, Nijmegen, Netherlands

[10] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Lab Med,Radboud Alzheimer Ctr, Nijmegen, Netherlands

[11] Maastricht Univ, Alzheimer Ctr Limburg, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Maastricht, Netherlands

[12] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol 1, Macedonia, Greece

[13] Alzheimer Hellas, Thessaloniki, Greece

[14] Univ Hosp Leuven, Leuven, Belgium

[15] Katholieke Univ Leuven, Dept Neurosci, Lab Cognit Neurol, Leuven, Belgium

[16] Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Clin Geriatr, Huddinge, Sweden

[17] Kings Coll London, Dept Old Age Psychiat Psychol & Neurosci, London, England

[18] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Mannheim, Germany

[19] Ctr Hosp & Univ Coimbra, Dementia Clin, Coimbra, Portugal

[20] Univ Coimbra, Fac Med, Coimbra, Portugal

[21] ICN Hosp Clin & Univ, Barcelona, Spain

[22] Univ Montpellier, CHU Montpellier, Montpellier, France

[23] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Molndal, Sweden

[24] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden

[25] UCL, Dept Neurodegenerat Dis, Queen Sq, London, England

[26] UCL, UK Dementia Res Inst, London, England

来源：

ALZHEIMERS & DEMENTIA | 2019年 / 15卷 / 06期

基金：

瑞典研究理事会; 欧洲研究理事会;

关键词：

Alzheimer; CSF; Tau; Amyloid; Neurofilaments; Inflammation; YKL-40; NEUROFILAMENT LIGHT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; CSF BIOMARKERS; TAU LEVELS; RECOMMENDATIONS; PROTEIN; BETA; DEMENTIA;

D O I：

10.1016/j.jalz.2019.01.015

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. Methods: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL). Median CSF sampling interval was 2.1 years. Results: CSF levels of t-tau, p-tau, NfL, and YKL-40 were 2% higher per each year of baseline age in controls (P <. 001). In AD, t-tau levels were 1% lower (P <. 001) and p-tau levels did not change per each year of baseline age. Longitudinally, only NfL (P <. 001) and YKL-40 (P <. 02) increased during the study period. Discussion: All four CSF biomarkers increase with age, but this effect deviates in AD for t-tau and ptau. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

引用

页码：742 / 753

页数：12

共 50 条

[31] The Amyloid-β Oligomer Count in Cerebrospinal Fluid is a Biomarker for Alzheimer's Disease
Wang-Dietrich, Lei
Funke, Susanne Aileen
Kuehbach, Katja
Wang, Kun
Besmehn, Astrid
Willbold, Sabine
Cinar, Yeliz
Bannach, Oliver
Birkmann, Eva
Willbold, Dieter
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2013, 34 (04) : 985 - 994
[32] Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease
Trombetta, Bianca A.
Wu, Chao-Yi
Kuo, Evan
de Geus, Matthijs B.
Dodge, Hiroko H.
Carlyle, Becky C.
Kivisakk, Pia
Arnold, Steven E.
[J]. ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2024, 10 (01)
[33] Objective Physical Function in the Alzheimer's Disease Continuum: Association with Cerebrospinal Fluid Biomarkers in the ALBION Study
Sampatakakis, Stefanos N.
Mamalaki, Eirini
Ntanasi, Eva
Kalligerou, Faidra
Liampas, Ioannis
Yannakoulia, Mary
Gargalionis, Antonios N.
Scarmeas, Nikolaos
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
[34] Cognitive and Cerebrospinal Fluid Alzheimer's Disease-related Biomarker Trajectories in Older Surgical Patients and Matched Nonsurgical Controls
Reese, Melody
Wong, Megan K.
Cheong, Vanessa
Ha, Christine I.
Wright, Mary Cooter
Browndyke, Jeffrey
Moretti, Eugene
Devinney, Michael J.
Habib, Ashraf S.
Moul, Judd W.
Shaw, Leslie M.
Waligorska, Teresa
Whitson, Heather E.
Cohen, Harvey J.
Welsh-Bohmer, Kathleen A.
Plassman, Brenda L.
Mathew, Joseph P.
Berger, Miles
[J]. ANESTHESIOLOGY, 2024, 140 (05) : 963 - 978
[35] Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease
Weinshel, Sarah
Irwin, David J.
Zhang, Panpan
Weintraub, Daniel
Shaw, Leslie M.
Siderowf, Andrew
Xie, Sharon X.
[J]. JOURNAL OF PARKINSONS DISEASE, 2022, 12 (04) : 1155 - 1167
[36] Different cerebrospinal fluid biomarker patterns in dementia patients with cerebrovascular disease and Alzheimer's disease
Bjerke, M.
Jonsson, M.
Zetterberg, H.
Blennow, K.
Schmidt, R.
Wallin, A.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 103 - 103
[37] Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum
Bonomi, Chiara Giuseppina
Assogna, Martina
Di Donna, Martina Gaia
Bernocchi, Francesca
De Lucia, Vincenzo
Nuccetelli, Marzia
Fiorelli, Denise
Loizzo, Stefano
Mercuri, Nicola Biagio
Koch, Giacomo
Martorana, Alessandro
Motta, Caterina
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2023, 92 (04) : 1385 - 1397
[38] Effect of Vascular Risk Factors on Blood-Brain Barrier and Cerebrospinal Fluid Biomarkers Along the Alzheimer's Disease Continuum: A Retrospective Observational Study
Ricci, Francesco
Martorana, Alessandro
Bonomi, Chiara G.
Serafini, Chiara
Mercuri, Nicola B.
Koch, Giacomo
Motta, Caterina
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2024, 97 (02) : 599 - 607
[39] CHOLINESTERASES IN CEREBROSPINAL-FLUID - A LONGITUDINAL-STUDY IN ALZHEIMER-DISEASE
ELBLE, R
GIACOBINI, E
SCARSELLA, GF
[J]. ARCHIVES OF NEUROLOGY, 1987, 44 (04) : 403 - 407
[40] Preanalytical Variables and Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid
Florkowski, Christopher M.
[J]. CLINICAL CHEMISTRY, 2015, 61 (05) : 686 - 688

← 1 2 3 4 5 →